Hualing Pharmaceutical-B (02552) Announces 2026 Interim Results: Commercialization Rapid Release to Achieve Commercial Implementation in Hong Kong and Macau Markets

Zhitong Finance App learned that on August 20, Hualing Pharmaceutical-B (02552) announced unaudited comprehensive interim results for the six months ended June 30, 2026. During the reporting period, independent commercialization of the core product Huatangning® (doglitin tablets) entered the large-scale deployment stage, with significant growth in revenue and gross margin; the global layout achieved key milestones, and the Hong Kong and Macau markets successfully achieved commercialization; a number of major clinical data appeared at top international academic conferences, and innovation continued to break through across the entire pipeline; core operating losses continued to narrow, and cash reserves remained steady, laying the foundation for the company's long-term sustainable development.

Huatangning® sold 3.05 million boxes in the first half of 2026, up 73% year on year; net sales were 378.9 million yuan, up 74% year on year. During the reporting period, total expenditure was approximately RMB 265.4 million, of which sales expenses were approximately RMB 126.9 million and R&D expenses were approximately RMB 66.8 million. Gross profit reached 234.3 million yuan, a year-on-year increase of 99%; gross margin increased sharply from 54.2% in the same period in 2025 to 61.8%, an increase of 7.6 percentage points; sales expenses were 126.9 million yuan, and the sales expenses ratio was 33.5%. Using gross profit after deducting sales and distribution expenses, the commercial sector achieved a profit of 107.4 million yuan in the first half of 2026, which doubled from 53.7 million yuan in the first half of 2025, and the profitability of independent commercialization continued to be realized.

The Hong Kong and Macau markets have completed approval and commercialization. Doglitidine (Hong Kong and Macau product name: MYHOMSIS®, Chinese Medicine®) was approved by the Hong Kong Department of Health in February 2026 and approved by the Macau Drug Administration in June 2026 to treat type 2 diabetes in adults. The company has completed distribution through Hong Kong hospitals and pharmacies, and issued its first prescription in Hong Kong in August 2026 to provide new treatment options for type 2 diabetics outside of mainland China.

Dr. Chen Li, founder and CEO of Hualing Pharmaceutical, said, “The first half of 2026 is a critical stage in Hualing Pharmaceutical's transition from innovation at the source to the realization of market value. The sales volume and revenue of dogliastine increased by more than 70% year on year, gross margin exceeded 60%, and commercial business profits doubled compared to the same period last year, verifying the company's successful transition from R&D innovation to rapid commercialization development in the field of chronic diseases. This also fully proves that, with the support of the country's full chain of innovative drug policies, the world's first innovative drug originating in China has strong and sustainable market vitality. At the same time, doglitin successfully landed in Hong Kong, China and Macau, China, officially embarking on an internationalization journey with Greater China as a hub and radiating the Southeast Asian and Spanish and Portuguese markets. China's original research and innovation drugs began to participate deeply in the global metabolic disease treatment market. Facing the future, the company will adhere to the homeostasis regulation of blood sugar as the foundation, promote a new pattern of homeostatic treatment of diabetes with a new generation of long-term GKA, fixed compound formulations and combined medications, build a human energy metabolism health pipeline matrix covering disease prevention, special diabetes, fatty liver disease and fatty hepatitis, cognitive impairment and weakness, and use artificial intelligence technology to continue to broaden the clinical boundaries and application scenarios of the blood sugar homeostasis technology platform to benefit patients with metabolic diseases at home and abroad.”